US20040049051A1 - Epothilone side components - Google Patents

Epothilone side components Download PDF

Info

Publication number
US20040049051A1
US20040049051A1 US10/457,098 US45709803A US2004049051A1 US 20040049051 A1 US20040049051 A1 US 20040049051A1 US 45709803 A US45709803 A US 45709803A US 2004049051 A1 US2004049051 A1 US 2004049051A1
Authority
US
United States
Prior art keywords
ddd
meoh
max
xxx
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/457,098
Inventor
Gerhard Hoefle
Hans Reichenbach
Klaus Gerth
Ingo Hardt
Florenz Sasse
Heinrich Steinmetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority to US10/457,098 priority Critical patent/US20040049051A1/en
Publication of US20040049051A1 publication Critical patent/US20040049051A1/en
Priority to US11/354,769 priority patent/US7235669B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Definitions

  • the invention concerns compounds which in the present context are designated epothilone side components, viz. compounds 5 to 13 and 16 to 39. These compounds can be produced by fermenting DSM 6773 in accordance to DE 41 38 042.8.
  • Epothilone H 2 (13) colorless amorphous solid; [ ⁇ ] 22 D -44.4 (c 0.25, MeOH); UV (MeOH) ⁇ max nm ( ⁇ ) 203 (14500), 236 (12200); IR (KBr) ⁇ max .
  • Epothilone C 5 (22) colorless amorphous solid; [ ⁇ ] 22 D -158.2 (c 0.5, MeOH); UV (MeOH) ⁇ max nm ( ⁇ ) 205 (19500), 247 (12700); IR (KBr) ⁇ max . 3447, 2972, 2927, 1737, 1690, 1450,1252,1181, 936 cm ⁇ 1 ; 1 H NMR (CDCl 3 , 400 MHz) ⁇ 6.93 (1H, s, H-19), 6.48 (1H, bs, H-17), 5.48 (1H, ddd,.

Abstract

The invention concerns compounds which can be obtained by fermenting DSM 6773, especially epothilones A1, A2, A8, A9, B10, C1, C2, C3, C4, C5, C6, C7, C8, C9, D1, D2, D5, G1, G2, H1, H2, I1, I2, I3, I4, I5, I6 and K and trans-epothilones C1 and C2.

Description

  • This application is a division of U.S. application Ser. No. 09/719,932, filed Mar. 21, 2001, allowed, which is the U.S. National Stage of PCT/EP99/04244, filed Jun. 18, 1999, which claims priority to DE 19826988.9, filed Jun. 18, 1998, the disclosure of each of which is incorporated by reference herein in its entirety.[0001]
  • The invention concerns compounds which in the present context are designated epothilone side components, viz. compounds 5 to 13 and 16 to 39. These compounds can be produced by fermenting DSM 6773 in accordance to DE 41 38 042.8.[0002]
  • Characterizing data of the compounds according to the invention will be compiled as follows. [0003]
  • Production: The processing of a raw epothilone mixture, which has been produced by fermenting DSM 6773 in a 900 1 fermentor, can be drawn schematically from FIGS. 1 to 2. [0004]
  • Activities: cf. table 1 [0005]
    Figure US20040049051A1-20040311-C00001
    Figure US20040049051A1-20040311-C00002
    Figure US20040049051A1-20040311-C00003
    Figure US20040049051A1-20040311-C00004
    Figure US20040049051A1-20040311-C00005
    Figure US20040049051A1-20040311-C00006
    Figure US20040049051A1-20040311-C00007
    Figure US20040049051A1-20040311-C00008
    Figure US20040049051A1-20040311-C00009
    Figure US20040049051A1-20040311-C00010
    Figure US20040049051A1-20040311-C00011
    Figure US20040049051A1-20040311-C00012
    Figure US20040049051A1-20040311-C00013
  • Epothilone A[0006] 1 (5): colorless amorphous solid; [α]22D-69 (c 0.1, MeOH); UV (MeOH) λmax nm (ε) 208 (19600), 247 (13600); IR (KBr) νmax 3437, 2959, 2931, 2876, 1732, 1710, 1455, 1259, 978 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.95 (1H, s, H-19), 6.60 (1H, bs, H-17), 5.68 (1H, dd, J=4.4, 4.0 Hz, H-15), 4.12 (1H, m, H-33), 3.71 (1H, m, H-7), 3.52 (1H, bs, 7-OH), 3.37 (1H, bd, J=7.5 Hz, 3-OH), 3.21 (1H, dq, J=7.7, 7.0 Hz, H-4), 3.02 (1H, ddd, J=9.2, 4.5, 2.8 Hz, H-13), 2.87 (1H, ddd, J=8.3, 4.5, 3.7 Hz, H-12), 2.78 (1H, dd, J=16.8, 4.3 Hz, H-2a), 2.70 (3H, s, H-21), 2.66 (1H, dq, J=3.9, 7.0 Hz, H-6), 2.65 (1H, dd, J=16.8, 5.2 Hz, H-2b), 2.16 (1H, ddd, J=15.4, 4.4, 2.8 Hz, H-14 a), 2.12 (3H, bs, H-27), 1.91 (1H, ddd, J=15.4, 9.2, 4.0 Hz, H-14b), 1.63 (1H, m, H-10a), 1.62 (2H, m, H-11), 1.59 (1H, m, H-9a), 1.52 (1H, m, H-10b), 1.39 (1H, m, H-8), 1.35 (1H, m, H-9b), 1.211 (3H, d; J=7.0 Hz, H-2-3), 1.207 (3H, d, J=7.0 Hz, H-24), 0.89 (3H, d, J=6.9 Hz, H-25); EIMS m/z 479 [M]+ (21), 3322 (31), 306 (65), 304 (47), 168 (45), 166 (73), 164 (100), 151 (30), 140 (35); HREIMS m/z 479.2317 (calcd. for C27H41NO5S, 479.2342).
  • Epothilone A[0007] 2 (6): colorless amorphous solid; [α]22D+12.0 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 210 (15100), 248 (15500); IR (KBr) νmax 3438, 2963, 2929, 2875, 1734, 1706, 1458, 1262, 981 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.98 (1H, s, H-19), 6.63 (1H, bs, H-17), 5.40 (1H, dd, J=8.3, 3.4 Hz, H-15), 4.26 (1H, ddd, J=8.5, 4.8, 4.7 Hz, H-3), 3.85 (1H, dd, J=7.9, 2.6 Hz, H-7), 3.54 (1H, bs, 3-OH), 3.09 (1H, dq, J=4.8, 7.0 Hz, H-4), 3.01 (1H, ddd, J-8.3, 4.8, 4.6 Hz, H-13), 2.98 (1H, dq, J=7.9, 7.0 Hz, H-6), 2.89 (1H, ddd, J=6.7, 4.6, 4.4 Hz, H12), 2.68 (3H, s, H-21), 2.60 (1H, dd, J=15.1, 8.5 Hz, H-2a), 2.52 (1H, bs, 7-OH), 2.50 (1H, dd, J=15.1, 4.7 Hz, H-2b), 2.18 (1H, ddd, J=15.0, 4.8,3.4 Hz, H-14a), 2.11 (3H, d, J=1.3 Hz, H-27), 1.82 (1H, ddd, J=15.0, 8.3, 8.1 Hz, H-14b), 1.63 (1H, m, H-8), 1.61 (2H, m, H-11a and H-10a), 1.46 (1H, m, H-1 lb), 1.39 (2H, m, H-9), 1.31 (1H, m, H-10b), 1.22 (3H, d, J=7.0 Hz, H-24), 1.15 (3H, d, J=7.0 Hz, H-22), 1.01 (3H, d, J=6.9 Hz, H-25); 13C NMR (CDCl3, 100 MHz) δ 216.2 (s, C-5), 170.1 (s, C-1), 164.9 (s, C-20), 152.0 (s, C-18), 137.0 (s, C-16), 120.3 (d, C-17), 116.5 (d, C-19), 76.7 (d, C-15), 75.6 (d, C-7), 69.1 (d, C-3), 57.1 (d, C-12), 54.3 (d, C-13), 50.3 (d, C-4), 49.6 (d, C-6), 39.4 (t, C-2), 35.5 (d, C-8), 32.2 (t, C-14), 29.6 (t, C-9), 27.6 (t, C-11), 23.9 (t, C-10), 19.2 (q, C-21), 18.0 (q, C-25), 15.6 (q, C-27), 13.9 (q, C-24), 12.4 (q, C-22); EIMS m/z 479 [M]+ (18), 322 (38), 306 (78), 304 (59), 168 (48), 166 (96), 164 (100), 151 (33), 140 (38); HREIMS m/z 479.2318 (calcd. for C27H41NO5S, 479.2342).
  • Epothilone A[0008] 8 (7): colorless amorphous solid; [α]22D-76.2 (c 1.0, MeOH); UV (MeOH) λmax nm (6) 210 (15300), 248 (15500); IR (KBr) νmax 3440, 2967, 2932, 2876, 1736, 1691, 1467, 1252, 979 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.95 (1H, s, H-19), 6.64 (1H, dd, J=15.6, 0.9 Hz, H-17), 6.52 (1H, dd, J=15.6, 6.6 Hz, H-16), 5.68 (1H, dddd, J=7.8, 6.6, 3.2, 0.9 Hz, H 15), 4.11 (1H, ddd, J=10.1, 6.6, 3.5 Hz, H-3), 3.78 (1H, ddd, J=5.2, 3.2, 3.2 Hz, H-7), 3.66 (1H, d,.1=6.6 Hz, 3-01-1), 3.23 (1H, dq, 1=5.2, 6.9 Hz,1-1-6), 3.08 (1H, ddd, J=7.3, 5.5,4.1 Hz, H-13), 2.90 (1H, ddd, 0.1=6.6, 4.6, 4.1 Hz, H-12), 2.69 (3H, s, H-21), 2.52 (1H, dd, J=14.7, 10.1 Hz, H-2a), 2.44 (1H, bd, J=3.2 Hz, 7-OH), 2.41 (1H, dd, J=14.7, 3.5 Hz, H-2b), 2.10 (1H, ddd, J=15.0, 5.5, 3.2 Hz, H-14a), 1.90 (1H, ddd, J=15.0, 7.8, 7.3 Hz, H-14b), 1.711 (1H, m, H-8), 1.65 (1H, m, H-11a), 1.50 (1H, m, H-10a), 1.47 (1H, m, H-11b), 1.40(2K m, H-9), 1.39 (1H, m, H-10b), 1.33 (3H, s, H-2-3)), 1.16 (3H, d, J=6.9 Hz, H-24), 1.08 (3H, s, H-22), 0.98 (3H, d, J=7.0 Hz, H-25); 13C NMR (CDCl3, 75 MHz) δ 220.3 (s, C-5), 170.7 (s, C-1), 166.5 (s, C-20), 152.2 (s, C-18), 128.4 (d, C-16), 125.9 (d, C-17), 116.4 (d, C-19), 75.0 (d, C-7), 73.6 (d, C-3), 72.7 (d, C-15), 57.3 (d, C-12), 54.1 (d, C-13), 52.6 (s, C-4), 43.8 (d, C-6), 38.9 (t, C-2), 36.3 (d, C-8), 32.5 (t, C-14), 30.3 (t, C-9), 26.7 (t, C-11), 24.0 (t, C-10), 21.3 (q, C-23), 21.0 (q, C-22), 19.3 (q, C-21), 17.1 (q, C-25), 14.5 (q, C-24); EIMS m/z 479 [M]+ XXX; HRDCIMS m/z 480.2401 (calcd. for C25H38NO6S, 480.2401).
  • Epothilone A[0009] 9 (8): colorless amorphous solid; [α]22D-37.6 (c 0.5, MeOH); UV (MeOH) λmax nm (ε) 211 (15500), 253 (14100); IR (KBr) νmax 3423, 2965, 2932, 2877, 1736, 1690, 1463, 1249, 1014, 979 cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.10 (1H, s, H-19), 6.72 (1H, dd, J=10.7, 4.3 Hz, 27-OH), 6.60 (1H, bs, H-17), 5.69 (1H, dd, J=11.6, 2.0 Hz, H-15), 5.59 (1H, d, J=6.6 Hz, 3-OH), 4.49 (1H, ddd, J=12.9, 4.3, 1.2 Hz, H-27a), 4.27 (1H, ddd, J=11.6, 6.6, 2.9 Hz, H-3), 4.11 (1H, ddd, J=12.9, 10.7, 1.0 Hz, H-27b), 3.71 (1H, ddd, J=4.8, 3.0, 2.8 Hz, H-7), 3.17 (1H, dq, J=3.0, 6.8 Hz, H-6), 3.04 (1H, ddd, J=9.7, 3.6, 2.2 Hz, H-13), 2.93 (1H, bs, 70H), 2.91 (1H, ddd, J=9.7, 3.6, 2.7 Hz, H-12), 2.72 (3H, s, H-21), 2.48 (1H, dd, J=14.2, 11.6 Hz, H-2a), 2.11 (111, dd, J=14.2, 2.9 Hz, H-2b), 2.03 (1H, ddd, J=14.7, 2.2, 2.0 Hz, H-14a), 1.86 (1H, m, H-11a), 1.85 (1H, m, -H-14b), 1.79 (1H, m, H-8), 1.52 (1H, m, H-10a), 1.37 (3H, m, H-9 and H-10b), 1.37 (3H, s, H-23), 1.36 (1H, m, H-11 lb), 1.19 (3H, d, J=6.8 Hz, H-24), 1.02 (3H, d,.1=7.1 Hz, H-25), 1.00 (3H, s, H-22); 13C NMR (CDCl3, 75 MHz) δ 220.5 (s, C-5), 170.2 (s, C-1), 167.5 (s, C-20), 150.7 (s, C-18), 138.9 (s, C-16), 125.2 (d, C-17), 119.5 ((d, C19), 76.7 (d, C-15), 73.4 (d, C-7), 70.4 (d, C-3), 57.7 (d, C-12), 57.2 (t, C-27), 55.3 (d, C-13), 54.2 (s, C-4), 4i:3 (d, C-6), 40.7 (t, C-2), 37.5 (d, C-8), 31.8 (t, C-14), 31.2 (t, C-9), 28.0 (t, C11), 23.7 (q, C-23), 23.2 (t, C-10), 19.2 (q, C-21), 16.8 (q, C-22), 15.8 (q, C-25), 13.5 (q, C-24); EIMS m/z 509 [M]+ (9), 491 (4), 322 (28), 321 (25), 180 (45), 167 (40), 166 (100), 165 (49), 154 (47), 138 (33); HREIMS m/z 509.2467 (calcd. for C26H39NO7S, 509.2447).
  • Epothilone B[0010] 10 (9): colorless amorphous solid; [α]22D-27 (c 0.15, MeOH); UV (MeOH) λmax 1M (g) 212 (15800), 247 (12500); IR (KBr) νmax 3434, 2962, 2930, 2876, 2858, 1733, 1692, 1461, 1259, 1052, 981 cm−1; 1H NMR (CDCl3, 600 MHz) δ 6.99 (1H, s, H-19), 6.60 (1H, bs, H-17), 5.42 (1H, dd, J=8.0, 3.0 Hz, H-15), 4.25 (1H, ddd, J=9.5, 6.3, 2.8 Hz, H-3), 4.23 (1H, bs, 3-OH), 3.77 (1H, ddd, J=4.0, 3.9, 3.8 Hz, H-7), 3.30 (1H, dq, J=4.0, 6.9 Hz, H6), 3.01 (2H, q, J=7.6 Hz, H-21), 2.81 (1H, dd, J=7.7, 4.6 Hz, H-13), 2.68 (1H, bs, 7-OH), 2.54 (1H, dd, J=13.9, 9.5 Hz, H-2a), 2.36 (1H, dd, J=13.9, 2.8 Hz, H-2b), 2.11 (1H, ddd, J=15.3, 4.6, 3.0 Hz, H-14a), 2.09 (3H, s, H-27), 1.91 (1H, ddd, J=15.3, 8.0, 7.7 Hz, H-14b), 1.74 (1H, m, H-8), 1.73 (1H, m, H-11a), 1.51 (1H, m, H-10a), 1.41 (1H, m, H-11 b), 1.39 (3H, t, J=7.6 Hz, H-28), 1.38 (3H, m, H-9 and H-10b), 1.37 (3H, s, H-23), 1.28 (3H, s, H-26),1.17 (3H, d, J=6.9 Hz, H-24), 1.09 (3H, s, H-22), 1.01 (3H, d, J=7.0 Hz, H-25); EIMS m/z 521 [M]+ (22), 449 (7), 350 (18), 334 (57), 248 (16), 234 (27), 196 (41), 182 (59), 180 (96), 178 (100), 166 (44), 154 (44); HREIMS m/z 521.2808 (calcd. for C28H43NO6S, 521.2811).
  • Epothilone G[0011] 1 (10): colorless amorphous solid; [α]22D-39.7 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 203 (15200), 236 (15100); IR(KBr) νmax3456, 2962, 2933, 2876, 1736, 1691, 1585, 1466, 1262, 980 cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.47 (1H, s, H-19), 6.33 (1H, bs, H-17), 5.42 (1H, dd, J=8.3, 2.9 Hz, H-15), 4.11 (1H, ddd, J=10.1, 6.1, 3.4 Hz, H-3), 3.78 (1H, bddd, J=5.2, 3.5, 3.5 Hz, H-7), 3.63) (1H, bd, J=6.1 Hz, 3-OH), 3.21 (1H, dq, J=5.2, 7.0 Hz, H-6), 3.00 (1H, ddd, J=7.7, 4.8, 4.2 Hz, H-13), 2.88 (1H, ddd, J=7.1, 4.2, 4.2 Hz, H12), 2.53 (1H, dd, J=14.8, 10.1 Hz, H-2a), 2.51 (1H, bd, J=3.5 Hz, 7-OH), 2.43 (1H, dd, J=14.8, 3.4 Hz, H-2b), 2.43 (3H, s, H-21), 2.07 (1H, ddd, J=15.1, 4.8, 2.9 Hz, H-14a), 1.99 (3H, d, J=1.3 Hz, H-27), 1.86 (1H, ddd, J=15.1, 8.3, 7.7 Hz, H-14b), 1.71 (1H, m, H-8), 1.69 (1H, m, H-1 la), 1.53 (1H, m, H-10a), 1.42 (1H, m, H-1 ib), 1.40 (3H, m, H-9 and H-10b), 1.34 (3H, s, H-23), 1.16 (3H, d, J=7.0 Hz, H-24), 1.09 (3H, s, H-22), 0.99 (3H, d, J=6.9 Hz, H25); 13C NMR, (CDCl3, 100 MHz) δ 220.1 (s, C-5), 170.5 (s, C-1), 161.0 (s, C-20), 1374 (s, C18), 136.7 (s, C-16), 135.9 (d, C-19), 116.4 (d, C-17), 76.4 (d, C-15), 74.9 (d, C-7), 73.7 (d, C3), 57.4 (d, C-12), 54.4 (d, C-13), 52.6 (s, C-4), 43.8 (d, C-6), 38.8 (t, C-2),″) 6.2 (d, C-8), 31.4 (t, C-14), 30.4 (t, C-9), 27.0 (t, C-11), 23.9 (t, C-10), 21.3 (q, C-23), 21.2 (q, C-22), 17.2 (q, C25), 15.8 (q, C-27), 14.4 (q, C-24), 13.8 (q, C-21); EIMS m/z 477 [M]+ (4), 405 (7), 290 (40), 152 (39), 150 (100), 14S (23), 124 (23); HREIMS m/z 477.2684 (calcd. for C26H39NO7, 477.2727).
  • Epothilone G[0012] 2 (11): colorless amorphous solid; [α]22D-22.6 (c 1.0, MeOH); W (MeOH) λmax nm (ε) 202 (21500), 236 (14800); IR (KBr) νmax3456, 2965, 2934, 2877, 1737, 1690, 1586, 1464, 1250, 980 cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.48 (1H, s, H-19), 6.33 (1H, bs, H-17), 5.43 (IF, dd, J=7.1, 3.6 Hz, H-15), 4.12 (1H, ddd, J=9.9, 6.4, 3.4 Hz, H-3), 3.77 (1H, ddd, J=4.7, 4.4, 4.1 Hz, H-7), 3.83 (1H, bd, J=6.4 Hz, 3-OH), 3.30 (1H, dq, J=4.7, 6.9 Hz, H-6), 2.78 (1H, dd, J=7.0, 5.4 Hz, H-13), 2.54 (1H, dd, J=14.3, 9.9 Hz, H-2a), 2.51 (1H, bd, J=4.1 Hz, 7-OH), 2.44 (3H, s, H-21), 2.40 (1H, dd, J=14.3, 3.4 Hz, H-2b), 2.03 (1H, ddd, J=15.2, 5.4, 3.611z, H-14a), 2.00 (3H, d, J=1.3 Hz, H-27), 1.92 (1H, ddd, J=15.1, 7.1, 7.0 Hz, H-14b), 1.71 (1H, m, H-8), 1.68 (1H, m, H-11a), 1.51 (1H, m, H-10a), 1.42 (1H, M, H-11b), 1.39 (3H, m, H-9 and H-10b), 1.35 (3H, s, H-23), 1.26 (3H, s, H-26), 1.16 (3H, d, J=6.9 Hz, H-24), 1.07 (3H, s, H-22), 0.99 (3H, d, J=7.0 Hz, H-25); 13CNMR (CDCl3, 100 MHz) δ 220.7 (s, C-5), 170.5 (s, C-1), 161.0 (s, C-20), 137.4 (s, C-18), 136.5 (s, C-16), 135.9 (d, C-19), 116.3 (d, C-17), 76.6 (d, C-15), 74.6 (d, C-7), 73.5 (d, C-3), 61.3 (s, C-12), 61.1 (d, C-13), 52.7 (s, C4), 43.4 (d, C-6), 39.0 (t, C-2), 36.5 (d, C-8), 32.0 (t, C-1), 31.8 (t, C-14), 30.8 (t, C-9), 22.8 (t, C-10), 22.9 (q, C-26), 21.0 (q, C-23), 20.8 (q, C-22), 17.2 (q, C-25), 15.9 (q, C-27), 14.1 (q, C-24), 13.8 (q, C-21); EIMS m/z 491 [M]+ (21), 419 (6), 320 (18), 304 (39), 166 (42), 152 (57), 150 (100), 149 (44), 148 (58), 124 (35), 109 (33); HREIMS m/z 491.2878 (calcd. for C27H41NO7, 491.2883).
  • Epothilone H[0013] 1 (12): colorless amorphous solid; [α]22D-84.2 (c 0.2, MeOH); WV (MeOH) λmax nm (ε) 203 (19600), 237 (12000); IR (KBr) νmax3436, 2933, 2880, 2860, 1734, 1688, 1585, 1251, 1007 cm−1; 1H NMR(CDCl3, 400 MHz) δ 7.47 (1H, s, H-19), 6.31 (1H, bs, H-17), 5.43 (1H, ddd, J=10.6, 10.2, 4.5 Hz, H-12), 5.36 (1H, dddd, J=10.6, 9.6, 5.0, 1.3 Hz, H-13), 5.30 (1H, dd, J=9.9, 2.0 Hz, H-15), 4.16 (1H, ddd, J=11.2, 5.3, 2.8 Hz, H-3), 3.73 (1H, ddd, .I=3.9, 2.5, 2.3 Hz, H-7), 3.12 (1H, dq, J=2.3, 6.9 Hz, H-6), 2.92 (1H, d, J=2.5 Hz, 7-OH), 2.91 (1H, d, J=5.3 Hz, 7-OH), 2.66 (1H, ddd, J=15.1, 9.9, 9.6 Hz, H-14a), 2.50 (1H, dd, J=15.4, 11.2 Hz, H-2a), 2.43 (3H, s, H-21), 2.37 (1H, dd, J=15.4, 2.8 Hz, H-2b), 2.23 (1H, m, H-14b), 2.18 (1H, m, H-11a), 2.01 (1H, m, H-11b), 2.08 (3H, d, J=1.3 Hz, H-27), 1.74 (1H, m, H-8), 1.65 (1H, m, H-10a ), 1.33 (1H, m, H-9a), 1.31 (3H, s, H-23), 1.19 (1H, m, H-10b), 1.18 (1H, m, H-9b), 1.17 (3H, d, J=6.9 Hz, H-24), 1.08 (3H, s, H-22), 0.99 (3H, d, J=7.1 Hz, H-25);13C NMR, see Table 1; EMS m/z 461 [M]+ (6), 310 (5), 274 (10), 273 (7), 171 (63), 152 (100), 148 (18), 111 (15); HREIMS m/z 461.2743 (calcd. for C26H39NO6, 461.2777).
  • Epothilone H[0014] 2 (13): colorless amorphous solid; [α]22D -44.4 (c 0.25, MeOH); UV (MeOH) λmax nm (ε) 203 (14500), 236 (12200); IR (KBr) νmax. 3436, 2967, 2935, 2880, 1734, 1690, 1586, 1251, 1007 cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.46 (1H, s, H-19), 6.30 (1H, bs, H-17), 5.23 (1H, dd, J=9.8, 2.1 Hz, H-15), 5.12 (1H, dd, J=10.1, 5.3 Hz, H-13), 4.20 (1H, ddd, J=10.8, 5.7, 2.9 Hz, H-3), 3.71 (1H, ddd, J=3.8, 2.6, 2.6 Hz, H-7), 3.14 (1H, dq, J=2.6, 6.9 Hz, H-6), 2.93 (d, J=5.7 Hz, 3-OH), 2.90 (1H, bd, J=2.6 Hz, 7-OH), 2.62 (1H, ddd, J=15.1, 9.8, 9.8 Hz, H-14a), 2.46 (1H, dd, J=15.1, 10.8 Hz, H-2a), 2.43 (3H, s, H-21), 2.32 (1H, dd, J=15.1, 2.9 Hz, H-2b), 2.29 (1H, m, H-11a), 2.19 (1H, bd, J=15.1 Hz, H-14b), 1.97 (3H, d, J=1.3 Hz, H-27), 1.87 (1H, m, H-1 lb), 1.73 (1H, m, H-8), 1.67 (1H, m, H-10a ), 1.65 (3H, bs, H-26), 1.32 (3H, s, H-23), 1.26 (2H, m, H-9), 1.24 (1H, m, H-10b), 1.18 (3H, d, J=6.9 Hz, H-24), 1.07 (3H, s, H-22), 1.00 (3H, d, J=7.0 Hz, H-25); 13C NMR (CDCl3, 100 MHz) δ 220.6 (s, C-5), 170.3 (s, C-1), 161.0 (s, C-20), 138.6 (s, C-12), 138.4 (s, C-16), 137.5 (s, C-18), 135.6 (d, C-19), 120.8 (d, C-13), 115.8 (d, C-17), 78.9 (d, C-15), 74.3 (d, C-7), 72.7 (d, C-3), 53.3 (s, C-4), 42.0 (d, C-6), 39.6 (t, C-2), 38.6 (d, C-8), 32.4 (t. C-14), 31.9 (t, C-9), 31.6 (t, C-Il), 25.6 (t, C-10), 23.0 (q, C-26), 22.8 (q, C-23), 18.8 (q, C-22), 16.1 (q, C-27), 15.9 (q, C-25), 13.8 (q, C-21), 13.6 (q, C-24); EIMS m/z 475 [M]+ (11), 288 (9), 287 (5), 188(7), 171 (32), 152 (100), 111 (10); HREIMS m/z 475.2913 (calcd. for C27H41NO6, 475.2934).
  • Epothilone C[0015] 1 (16): colorless amorphous solid; [α]22D -114.0 (c 10.0, MeOH); UV (MeOH) λmax nm (ε) 211 (16500), 248 (12500); IR (KBr) νmax3440, 2933, 2877, 2858, 1730, 1708, 1457, 1244, 981 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.96 (1H, s, H-19), 6.56 (1H, bs, H-17), 5.47 (1H, dd, J=9.2, 3.0 Hz, H-15), 5.43 (1H, m, H-12), 5.40 (1H, m, H-13), 4.40 (1H, ddd, J=6.2, 6.1, 6.1 Hz, H-3), 3.69 (1H, dd, J=5.7, 3.6 Hz, H-7), 3.01 (1H, dq, J=5.7, 6.9 Hz, H-6), 3.01 (1H, bs, 3-OH), 2.84 (1H, dq, J=5.2, 7.0 Hz, H-4), 2.68 (3H, s, H-21), 2.66 (1H, ddd,.1=16.4, 9.2, 7.3 Hz, H-14a), 2.64 (1H, dd, J=15.9, 7.1 Hz, H-2a), 2.54 (1H, dd, J=15.9, 6.1 Hz, H-2b), 2.38 (1H, bd, J=16.4 Hz, H-14b), 2.35 (1H, bs, 7-OH), 2.07 (3H, bs, H-27), 2.03 (2H, m, H-i 1), 1.62 (1H, m, H-10a), 1.53 (1H, m, H-8), 1.35 (1H, m, H-9a), 1.22 (1H, M, H-9b), 1.19 (3H, d, J=6.9 Hz, H-24), 1.14 (3H, d, J=6.9 Hz, H-23), 1.10 (1H, m, H-10b), 0.95 (3H, d, J=6.9 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 463 [M]+ (5), 324 (8), 290 (8), 204 (7), 168 (100), 164 (15), 139 (36); HREIMS m/z 463.2381 (calcd. for C23H37NO5S, 463.2392).
  • Epothilone D[0016] 1 (17): colorless amorphous solid; [α]22D -118.6 (c 0.5, MeOH); UV (MeOH) λmax n-m (ε) 208 (18300), 249 (11900); IR (KBr) νmax3439, 2965, 2934, 2877, 1729, 1707, 1456, 1250, 980 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.98 (1H, s, H-19), 6.56 (1H, bs, H-17), 5.51 (1H, dd, J=9.5, 3.4 Hz, H-15), 5.16 (1H, dd, J=8.0, 4.2 Hz, H-13), 4.42 (1H, ddd, J=7.1, 6.3, 5.5 Hz, H-3), 3.70 (1H, dd, J=6.5, 2.9 Hz, H-7), 3.07 (1H, dq, J=6.5, 6.9 Hz, H-6), 2.95 (1H, dq. J=4.7, 7.0 Hz, H-4), 2.71 (3H, s, H-21), 2.69 (1H, dd, J=16.0, 6.3 Hz, H-2a), 2.64 (1H, m, H-14a), 2.59 (1H, dd, J=16.0, 7.1 Hz, H-2b), 2.46 (1H, bs, 3-OH), 2.38 (1H, bd, J=16.0 Hz, H-14b), 2.19 (1H, ddd, J=13.3,8.6,5.7 Hz,H-11a), 2.10(3H, d, J=1.4 Hz, H-27), 2.02 (1H, bs, 7-OH), 1.91 (1H, ddd, J=13.3, 6.0, 6.0 Hz, H-1 lb), 1.68 (1H, m, H-10a ), 1.66 (3H, bs, H-26), 1.53 (1H, m, H-8), 1.37 (1H, m, H-9a), 1.26 (1H, m, H-9b), 1.24 (3H, d, J=6.9 Hz, H-24), 1.19 (1H, m, H-10b), 1.14 (3H, d. J=7.0, H-23), 0.99 (3H, d, J=6.9 Hz, H-25); 13C NMR (CDCl3, 100 MHz) δ 217.0 (s, C-5), 169.7 (s, C-1), 165.0 (s, C-20), 152.2 (s, C18), 1-38.5 (s, C-12), 137.7 (s, C-16), 120.7 (d, C-13), 120.1 (d, C-17), 116.3 (d, C-19), 78.8 (d, C-15), 77.2 (d, C-7), 67.7 (d, C-3), 52.1 (d, C-4), 46.5 (d, C-6), 40.6 (t, C-2), 37.6 (d, C-8), 32.3 (t, C-14), 31.8 (t, C-11), 29.5(t, C-9), 25.5 (t, C-10), 23.1 (q, C-26), 19.2 (q, C-21), 15.5 (q, C27), 16.6 (q, C-25), 14.5 (q, C-24), 9.7 (q, C-23); EIMS m/z 477 [M]+ (13), 304 (19), 303 (31), 218 (40), 204 (41), 168 (100), 164 (45), 157 (25), 139 (18); HREIMS m/z 477.2544 (calcd. for C26H39NO5S, 477.2549).
  • Epothilone C[0017] 2 (18): colorless amorphous solid; [α]22D -11.6 (c 10.0, MeOH); UV (MeOH) λmax nm (ε) 212 (15500), 249 (12100); IR (KBr) νmax3428, 2962, 2929, 2877, 2859, 1734, 1705, 1460, 1251, 9S2 cm−1;1H NM (CDCl3, 300 MHz) δ 6.99 (1H, s, H-19), 6.66 (1H, bs, H-17), 5.55 (1H, ddd, J=10.4, 9.2, 6.1 Hz, H-12), 5.38 (1H, ddd, J=10.4, 9.3, 6.2 147, H-13), 5.22 (1H, dd, J=8.8, 2.8 Hz, H-15), 4.42 (1H, dddd, J=9.4, 5.6, 4.2, 4.1 Hz, H-3), 3.93 (1H, d, J=5.6 Hz, 3-OH), 3.86 (1H, m, H-7), 3.15 (1H, bs, 7-OH), 3.12 (1H, dq, J=4.2, 7.0 Hz, H-4), 3.00 (1H, dq, J=6.9, 7.0 Hz, H-6), 2.70 (3H, s, H-21), 2.62 (1H, dddd, J=15.1, 9.3, 8.8, 0.8 Hz, H-14a), 2.58 (1H, dd, J=15.4, 9.4 Hz, H-2a), 2.38 (1H, dd, J=15.4, 4.1 Hz, H-2b), 2.31 (1H, ddd,.1=15.1, 6.2, 2.8 Hz, H-14b), 2.08 (3H, d, J=1.3 Hz, H-27), 2.15 (1H, m, H-11a), 2.04 (1H, m, H-11b), 1.71 (1H, m, H-8), 1.59 (1H, m, H-10a), 1.43 (1H, m, H-9a), 1.31 (114, m, H-9b), 1.26 (3H, d, J=7.0 Hz, H-24), 1.15 (3H, d, J=7.0 Hz, H-23), 1.11 (1H, m, H-10b), 1.00 (3H, d, J=6.9 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 463 [M]+ (7), 324 (7), 306 (8), 290 (17), 168 (100), 164 (14), 139 (27); HREIMS m/z 463.2392 (calcd. for C25H37NO5S, 463.2392).
  • Epothilone D[0018] 2 (19): colorless amorphous solid; [α]22D -12.5 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 210 (15400), 248 (11200); IR (KBr) νmax 3436, 2965, 2930, 2877, 1732, 1705, 1458, 1253, 980 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.97 (1H, s, H-19), 6.56 (1H, bs, H-17), 5.18 (IF, dd, J=7.9, 4.9 Hz, H-15), 5.18 (1H, ddd, J=9.6, 5.4, 1.0 Hz, H-13), 4.27 (1H, m, H-3), 3.88 (1H, dd, J=5.6, 4.6 Hz, H-7), 3.19 (1H, bs, 3-OH), 3.07 (1H, dq, J=4.3, 7.0 Hz, H-4), 2.95 (1H, dq, J=5.6, 7.0 Hz, H-6), 2.70 (3H, s, H-21), 2.62 (1H, dd, J=14.9, 7.8 Hz, H-2a), 2.56 (1H, ddd, J=14.7, 9.6, 7.9 Hz, H-14a), 2.43 (1H, dd, J=14.9, 5.6 Hz, H-2b), 2.38 (1H, bs, 7-OH), 2.26 (1H, ddd, J=14.5, 5.4, 4.9 Hz, H-14b), 2.19 (1H, ddd, J=13.0, 10.4, 5.4 Hz, H-11a), 2.10 (3H, d, 0.1=1.4 Hz, H-27), 1.95 (1H, ddd, J=13.0, 10.3, 5.3 Hz, H-11b), 1.72 (1H, m, H—S), 1.68 (3H, bs, H-26), 1.61 (1H, m, H-10a ), 1.39 (2H, m, H-9), 1.21 (1H, m, H-10b), 1.19 (3H, d, J=6.9 Hz, H-24),1.17 (3H, d. J=7.0, H-22),1.00 (3H, d, J=6.9 Hz, H-25J; 13C NMR (CDCl3, 100 MHz) δ 216.8 (s, C-5), 170.4 (s, C-1), 164.9 (s, C-20), 152.3 (s, C-18), 139.8 (s, C-12), 137.5 (s, C-16), 120.5 (d, C-17), 119.2 (d, C-13), 116.3 (d, C-19), 80.0 (d, C-15), 74.3 (d, C-7), 69.7 (d, C-3), 48.6 (d, C-4), 48.4 (d, C-6), 39.9 (t, C-2), 36.6 (d, C-8), 32.2 (t, C-14), 32.7 (t, C-11), 30.9 (t, C-9), 26.0 (t, C-10), 23.6 (q, C-26), 19.2 (q, C-21), 15.4 (q, C-27), 17.1 (q, C-25), 12.4 (q, C-24), 12.7 (q, C-23); EIMS m/z 477 [M]+ (22), 304 (19), 303 (17), 218 (22), 204 (25), 163 (100), 164 (28), 157 (31), 139 (21); HREIMS m/z 477.2545 (calcd. for C26H39NO5S, 477.2549).
  • Epothilone C[0019] 3 (20): colorless amorphous solid; [α]22D -62.1 (c 5.0, MeOH); UV (MeOH))λmax nm (ε) 212 (16200), 248 (12300); IR (KBr) νmax 3432, 2928, 2878, 2858, 1736, 1698, 1252, 1040 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.95 (1H, s, H-19), 6.56 (1H, bs, H-17), 5.44 (1H, ddd, J=10.9, 10.3, 5.4 Hz, H-12), 5.33 (1H, ddd, J=10.9, 9.3, 4.6 Hz, H-13), 5.23 (1H, dd, J=9.5, 2.2 Hz, H-15), 4.36 (1H, ddd, J=11.3, 5.6, 2.3 Hz, H-3), 4.04 (1H, d, J=5.6 Hz, 3-OH), 3.93 (1H, ddd,.1=9.5, 2.3, 1.4 Hz, H-7), 3.56 (1H, bd, J=2.3 Hz, 7-OH), 2.70 (1H, dd, J=18.0, 1.4 Hz, H-6a), 2.67 (3H, s, H-21), 2.61 (1H, ddd, J=15.3, 9.5, 9.3 Hz, H-14a), 2.38 (1H, dd,.1=14.3, 11.3 Hz, H-2a), 2.36 (1H, dd, J=18.0, 9.5 Hz, H-6b), 2.28 (1H, bd, J=15.3 Hz, H-14b), 2.12 (1H, m, H-11a), 2.06 (1H, dd, J=14.3, 2.3 Hz, H-2b), 2.03 (3H, d, J=1.3 Hz, H-27),1.96 (1H, m, H-1 lb), 1.75 (1H, m, H-8), 1.54 (1H, m, H-10a), 1.26 (1H, m, H-9a), 1.25.(3H, s, H-23), 1.17 (1H, m, H-10b), 1.15 (1H, m, H-9b), 1.03 (3H, s, H-22), 0.91 (3H, d. J=6.8 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 463 [M]+ (28), 290 (14), 168 (100), 164 (36), 157 (44). 151 (25), HREIMS m/z 463.2379 (calcd. for C25H37NO5S, 463.2392).
  • Epothilone C[0020] 4 (21): colorless amorphous solid; [α]22D -75.6 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 212 (17200), 248 (12500); IR (KBr) νmax 3434, 2974, 2932, 2859, 1735, 1686, 1252, 1046 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.96 (1H, s, H-19), 6.60 (1H, bs, H-17), 5.43 (1H, m, H-12), 5.40 (1H, m, H-13), 5.26 (1H, dd, J=9.6, 2.3 Hz, H-15), 4.41 (1H, ddd, J=11.4, 5.8,2.5 Hz, H-3), 3.78 (1H, m, H-7), 3.70 (1H, bs, 3-OH), 3.46 (1H, d, J=0.9 Hz, 7-OH), 3.01 (1H, dq, J=0.5, 7.0 Hz, H-6), 2.69 (3H, s, H-21), 2.66 (1H, ddd, J=15.3, 9.6, 8.8 Hz, H-14a), 2.47 (1H, dd, J=14.5, 11.4 Hz, H-2a), 2.29 (1H, m, H-1.4b), 2.25 (1H, dd, J=14.5, 2.5 Hz, H-2b), 2.24 (1H, m, H-11a), 2.07 (3H, d, J=1.4 Hz, H-27), 1.96 (1H, m, H-11b), 1.51 (2H, m, H-8), 1.44 (2H, m, H-10), 1.37 (2H, m, H-9), 1.32 (3H, s, H-23), 1.17 (3H, d, J=7.0 Hz, H-24), 1.07 (3H, s, H-22); 13C NMR , see Table 1; EIMS m/z 463 [M]+ (7), 276 (15), 171 (33), 168 (100), 164 (23), 151 (22), 111 (13); HREIMS m/z 463.2373 (calcd. for C25H37NO5S, 463.2392).
  • Epothilone C[0021] 5 (22): colorless amorphous solid; [α]22D -158.2 (c 0.5, MeOH); UV (MeOH) λmax nm (ε) 205 (19500), 247 (12700); IR (KBr) νmax. 3447, 2972, 2927, 1737, 1690, 1450,1252,1181, 936 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.93 (1H, s, H-19), 6.48 (1H, bs, H-17), 5.48 (1H, ddd,. J=10.7, 6.2, 6.2 Hz, H-12), 5.39 (1H, m, H-13), 5.37 (1H, M, H-9), 5.34 (1H, dd, J=8.0, 2.3 Hz, H-15), 4.29 (1H, dd, J=6.0, 2.6 Hz, H-7), 4.09 (1H, ddd, J=10.8, 7.1, 2.9 Hz, H-3), 3.59 (1H, d, J.=7.1 Hz, 3-OH), 3.17 (1H, dq, J=6.0, 6.9 Hz, H-6), 2.68 (3H, s, H-21).2.54 (1H, ddd, J=15.2, 8.1, 8.0 Hz, H-14a), 2.44 (1H, bs, 7-OH), 2.42 (1H, dd, J=15.1, 2.9 Hz, H-2a), 2.41 (1H, ddd, J=15.2, 2.3, 2.3 Hz, H-14b), 2.34 (1H, dd, J=15.1, 10.8 Hz, H2b), 2.20 (1H, m, H-10a ), 2.18 (2H, m, H-11), 2.12 (1H, m, H-10b), 2.06 (3H, bs, H-27), 1.67 13 (3H, bs, H-25), 1.27 (3H, s, H-23), 1.21 (3H, d, J=6.9 Hz, H-24), 1.15 (311, s, H-22); 13C NMR, see Table 1; EIMS m/z 475 [M]+ (6), 392 (7), 304 (6), 288 (33), 204 (76), 171 (19), 168 (100), 164 (12); REIMS m/z 475.2380 (calcd. for C26H37NO5S, 475.2392).
  • Epothilone D[0022] 5 (23): colorless amorphous solid; [α]22D -150 (c 0.2, MeOH); UV (MeOH)) λmax nm (ε) 205 (23300), 248 (13600); IR (KBr) νmax 3439, 2967, 2927, 1736, 1690, 1451, 1254, 1181, 987 cm−1; 1H NMR (CDCl3, 400 MHz) 5; 6.94 (1H, s, H-19), 6.51 (1H, bs, H-17), 5.34 (1H, bs, H-9), 5.29 (1H, dd, J=8.0, 2.4 Hz, H-15), 5.16 (1H, dd, J=8.2, 6.2 Hz, H-13), 4.30 (1H, bd, J=4.9 Hz, H-7), 4.19 (1H, ddd, J=10.8, 7.6, 3.0 Hz, H-3), 3.68 (1H, d, J=7.6 Hz, 3-OH), 3.17 (1H, dq, J=4.9, 7.0 Hz, H-6), 2.69 (3H, s, H-21), 2.65 (1H, d, J=2.1 Hz, 7-OH), 2.56 (1H, ddd, J=16.2, 8.2, 8.0 Hz, H-14a), 2.40 (1H, dd, J=15.0, 3.0 Hz, H-2a), 2.39 (1H, bd, J=16.2 Hz, H-14b), 2.34 (1H, dd, J=15.0, 10.8 Hz, H-2b), 2.25 (2H, m, H-10a and H-11a), 2.20(1H, m, H-10b), 2.17 (1H, m, H-11b), 2.05 (3H, d, J=1.0 Hz, H-27), 1.69 (3H, bs, H-25), 1.68 (3H, bs, H-26), 1.29 (3H, s, H-23), 1.23 (3H, d, J=7.0 Hz, H-24), 1.16 (3H, s, H-22); 13C NMR, see Table 1; EIMS m/z 489 [M]+ (4), 406 (4), 338 (7), 302 (13), 218 (35), 171 (10), 168 (100), 153 (20), 125 (10); HREIMS m/z 489.2536 (calcd. for C27H39NO5S, 489.2549).
  • Epothilone C[0023] 6 (24): colorless amorphous solid; [α]22 D -205.2 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 218 (24600), 237 (28800); IR (KBr) νmax 3435, 2967, 2927, 2882, 1732, 1688, 1465, 1258, 988 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.97 (1H, s, H-19), 6.58 (1H, bs, H-17), 6.43 (1H, dd, 15.5, 10.8 Hz, H-11), 6.11 (1H, dd, J=10.8, 10.6 Hz, H-12), 5.75 (1H, ddd, J.=15.5,8.3,5.6 Hz, H-10), 5.34 (1H, m, H-13), 5.34 (1H, dd, J=9.7, 2.4 Hz, H-15), 4.16 (1H, ddd, .J=9.2, 4.9, 4.3 Hz, H-33), 3.74 (1H, ddd, J=2.2, 2.1, 1.7 Hz, H-7), 3.24 (1H, dq, J=2.1, 6.9 Hz, H-6), 3.06 (1H, d, J=2.2 Hz, 7-OH), 2.93 (1H, d, J=4.9 Hz, 3-OH), 2.78 (1H, dddd, J=14.1, 9.9 9.7, 0.7, H-14a), 2.71 (3H, s, H-21), 2.48 (1H, m, H-9a), 2.47 (1H, dd, J=15.5, 9.2 Hz, H-2a), 2.40 (1H, dd, J=15.5, 4.3 Hz, H-2b), 2.38 (1H, bdd, J=14.1, 7.8 Hz, H-14b), 2.11 (3H, d, J=1.3 Hz, H-27), 1.96 (1H, m, H-8), 1.33 (3H, s, H-23), 1.11 (3H, d, J=6.9 Hz, H-24), 1.06 (3H, s, H-22), 1.05 (3H, d, J=6.8 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 475 [M]+ (13), 387 (2), 316 (4), 288 (15), 230 (16), 204 (9), 171 (18), 168 (100), 164 (14), 151 (17); HREIMS m/z 475.2361 (calcd. for C26H37NO5S, 475.2392).
  • Epothilone C[0024] 7 (25): colorless amorphous solid; [C]22D -XXX (c 2.0, MeOH); UV (MeOH) λmax nm (ε) XXX (XXX), XXX (XXX); IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.01 (1H, s, H-19), 6.66 (1H, bs, H-17), 5.59 (1H, ddd, J=11.1, 11.1, 3.8 Hz, H-12), 5.40 (1H, dd, J=11.1, 9.2, H-13), 5.03 (1H, d, J=9.3 Hz, H-15), 4.62 (1H, dd, J=9.3, 9.2 Hz, H-14), 4.18 (1H, bd, J=11.0 Hz, H-3), 3.72 (1H, bs, H-7), 3.20 (1H, bs, 3-OH), 3.09 (1H, dq, J=1.9, 6.8 Hz, H-6), 3.00 (1H, bs, 7-OH), 2.69 (3H, s, H-21), 2.47 (1H, dd, J=14.8, 11.0 Hz, H-2a), 2.32 (1H, dd, J=14.8, 2.6 Hz, H-2b), 2.27 (1H, m, H-11a), 2.19 (3H, bs, H-27), 2.13 (1H, m, H-11b), 1.76 (1H, m, H-8), 1.70 (1H, m, H-10a ), 1.35 (1H, m, H-9a), 1.32 (3H, s, H-23), 1.23 (1H, m, H-9b), 1.21 (1H, m, H-10b), 1.18 (3H, d, J=6.8 Hz, H-24), 1.08 (3H, s, H-22), 1.00 (3H, d,.]=6.9 Hz, H-25); EIMS m/z 493 [M]+XXX; HREIMS m/z 493.XXX (calcd. for C26H39NO6S, 493.2498).
  • Epothilone C[0025] 9 (26): colorless amorphous solid; [α]22D -75.2 (c 2.5, MeOH); UV (MeOH) λmax nm (ε) 210 (16803), 248 (17800); IR (KBr) νmax 3443, 2932, 2881, 1734, 1689, 1465, 1255,1183, 976 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.93 (1H, s, H-19), 6.62 (1H, dd, J=15.6, 0.6 Hz, H-17), 6.49 (1H, dd, J=15.6, 6.6 Hz, H-16), 5.52 (1H, dddd, J=9.5, 6.6, 2.8, 0.6 Hz, H-15), 5.42 (1H, m, H-12), 5.41 (1H, m, H-13), 4.13 (1H, ddd, J=11.0, 5.3, 2.8 Hz, H-3), 3.69 (1H, ddd, J=3.7, 2.8, 2.5 Hz, H-7), 3.11 (1H, dq, J=2.5, 6.8 Hz, H-6), 2.95 (1H, d, J=5.3 Hz, 3-OH), 2.90 (1H, d, J=2.8 Hz, 7-OH), 2.69 (3H, s, H-21), 2.67 (1H, ddd, 0.1=14.9, 9.5, 8.4 Hz, H-14a), 2.48 (1H, dd, J=15.6, 11.0 Hz, H-2a), 2.33 (1H, dd, J=15.6, 2.8 Hz, H-2b), 2.30 (1H, bd, J=14.9 Hz, H-14b), 2.14 (1H, m, H-11a), 2.03 (1H, m, H-11b), 1.71 (1H, m, H-8), 1.63 (1H, m, H-10a ), 1.31 (1H, m, H-9a), 1.29 (3H, s, H-23), 1.17 (3H, d, J=6.8 Hz, H-24), 1.16 (1H, m, H-10b), 1.14 (1H, m, H-9b), 1.05 (3H, s, H-22), 0.97 (3H, d, J=7.1 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 463 [M]+ (21), 310 (10), 276 (21), 171 (83), 154 (100), 150 (27), 111 (18); HREIMS m/z 463.2382 (calcd. for C25H37NO5S, 463.2392).
  • Epothilone C[0026] 9, (27): colorless amorphous solid; [α]22D-93.4 (c 1.0, MeOH); UV (MeOH) λmax nm (ε) 209 (15200), 254 (15700); IR (KBr)) νmax 3416, 2966, 2932, 1736, 1689, 1463, 1249, 1011 cm−1; 1H NMR (CDCl3, 400 MHz) δ 7.06 (1H, s, H-19), 6.65 (1H, bs, H-1 7), 6.56 (1H, dd, J=10.6, 4.4 Hz, 27-OH), 5.55 (1H, d, J=6.2 Hz, 3-OH), 5.52 (1H, dd, J=11.6, 2.0 Hz, H-15), 5.44 (1H, dddd, J=11.2, 10.7, 3.1, 1.7 Hz, H-12), 5.35 (1H, dddd, J=11.0, 10.7, 3.9, 1.7 Hz, H-13), 4.47 (11-1, ddd, J=12.5, 4.4, 1.3 Hz, H-27a), 4.35 (1H, ddd, J=11.7, 6.2, 2.6 Hz, H-3), 4.20 (1H, ddd, J=12.5, 10.6, 0.9 Hz, H-27b), 3.63 (1H, ddd, J=4.6, 1.8, 0.9 Hz, H-7), 3.24 (1H, d, J=1.8 Hz, 7-OH), 3.13 (1H, dq, J=0.9, 6.8 Hz, H-6), 2.80 (1H, ddd, J=14.8, 11.6, 11.0 Hz, H-14a), 2.71 (3H, s, H-21), 2.40 (1H, dd, J=14.4, 11.7 Hz, H-2a), 2.24 (1H, m, H I 1a), 2.06 (1H, dd, J=14.4, 2.6 Hz, H-2b), 2.01 (1H, ddd; J=14.8, 3.9, 2.0 Hz, H-14b), 2.00 (1H, m, H-1 lb), 1.77 (1H, m, H-8), 1.69 (1H, m, H-10a ), 1.35 (1H, m, H-9a), 1.35 (3H, s, H 23), 1.19 (1H, m, H-10b), 1.19 (3H, d, J=6.8 Hz, H-24), 1.18 (1H, m, H-9b), 1.01 (3H, d, J=7.1 Hz, H-25), 0.98 (3H, H-22); 13C NMR, see Table 1; EIMS m/z 493 [M]+ (17), 306′(64), 184 (50), 171 (30), 167 (38), 166 (100), 138 (12); HREIMS m/z 493.2502 (calcd. for C26H39NO6S, 493.2498).
  • trans-Epothilone C[0027] 1, (28): colorless amorphous solid; [α]22D -84 (c 0.2, MeOH); UV (MeOH) λmax nm (ε) 211 (17400), 248 (12900);1R (KBr) νmax 3433, 2961, 2933, 2879, 1730, 1708, 1457, 1251, 975 cm−1; 1H NMR (CDCl3, 600 MHz) δ 7.00 (1H, s, H-19), 6.64 (1H, bs, H17), 5.45 (1H, ddd, J=15.2, 6.5, 6.5 Hz, H-12), 5.42 (1H, dd, J=6.4, 3.7 Hz, H-15), 5.35 (1H, dt, J=15.2, 7.1 Hz, H-13), 4.42 (1H, m, H-3), 3.58 (1H, ddd, J=8.1, 7.9, 2.8 Hz, H-7), 3.24 (1H, m, H-6), 3.14 (1H, dq, J=4.0, 6.9 Hz, H-6), 2.92 (1H, d, J=7.9 Hz, 7-OH), 2.71 (3H, s, H-21), 2.71 (2H, m, H-2), 2.53 (2H, m, H-14), 2.17 (1H, d, J=2.17 Hz, 3-OH), 2.11 (1H, m, H-11a), 2.06 (3H, bs, H-27), 1.93 (1H, m, H-1 lb), 1.68 (1H, m, H-9a), 1.65 (1H, m, H-10a ), 1.33 (1H, m, H-8), 1.26 (3H, d, J=6.8 Hz, H-24), 1.16 (1H, m, H-10b), 1.12(3K d, J=6.9 Hz, H-22), 1.07 (1H, m, H-9b), 1.00 (3H, d, J=6.8 Hz, H-25); 13C NMR, see Table 1; EIMS m/z 463 [M]+ (6), 290 (21), 289 (20), 204 (23), 194 (19), 190 (22), 168 (100), 164 (48), 157 (14), 152 (19), 151 (17), 139 (15), 111 (18); HREIMS m/z 463.2371 (calcd. for C25H37NO5S, 463.2392).
  • trans-Epothilone C[0028] 2 (29): colorless amorphous solid; [α]22D -3 (c 1.5, MeOH); UV (MeOH) λmax nm (ε) 211 (15800), 248 (11900); IR (KBr) νmax3435, 2963, 2931, 2878, 1731, 1706, 1457,1273, 979 cm−1; 1H NMR (CDCl3, 600 MHz) δ 6.99 (1H, s, H-19), 6.57 (1H, bs, H 17), 5.56*(] H, ddd, J=15.1, 7.4, 7.0 Hz, H-12), 5.41 (1H, ddd, J=15.1, 7.0, 6.9 Hz, H-13), 5.41 (1H, dd, J=7.7, 2.8 Hz, H-15), 4.13 (1H, dddd, J=6.7, 6.2, 5.6, 5.1 Hz, H-3), 3.78 (1H, ddd, J=8.2, 6.5, 1.9 Hz, H-7), 3.18 (1H, d, J=5.6 Hz, 3-OH), 3.06 (1H, dq, J=8.2, 7.1 Hz, H-6), 2.98 (1H, dq, J=6.2, 7.0 Hz, H-4), 2.71 (3H, s, H-21), 2.64 (1H, dd, J=15.1, 6.7 Hz, H2a), 2.54 (1H, dd, J=15.1, 5.1 Hz, H-2b), 2.44 (2H, m, H-14), 2.22 (1H, dddd, J=13.8, 7.0, 6.2, 2.9 Hz, H-11a), 2.10 (3H, d, J=1.1 Hz, H-27), 2.09 (H, d, J=6.5 Hz, 7-OH), 1.88 (1H, dddd, J=13.8, 10.9, 7.4, 2.9 Hz, H-1 lb), 1.65 (1H, m, H-8), 1.63 (1H, m, H-10a ), 1.56 (1H, dddd, J=12.7, 12.7, 3.9, 3.9 Hz, H-9a), 1.20 (3H, d, J=7.1 Hz, H-24), 1.15 (3H, d, J=7.0 Hz, H-23), 1.13 (1H, m, H-10b), 1.04 (1H, m, H-9.b), 1.01 (3H, d, J=7.0.Hz, H-25);13C NMR, see Table 1; EIMS m/z 463 [M]+ (13), 290 (11), 190 (10), 168 (100), 164 (20), 157 (26), 139 (17); HREIMS m/z 463.2383 (calcd. for C25H37NO5S, 463.2392).
  • Epothilone I[0029] 1, (30): colorless amorphous solid; [α]22D -XXX (c XXX, MeOH); UV (MeOH) λmax f nm (ε) XXX; IR(KBr) νmaxXXX cm−1; 1H NMR (CDCl3, 300 MHz) 6.96 (1H, s, H-1 9), 6.54 (1H, bs, H-1 7), 5.49 (Iii, ddd, J=10.3, 7.3, 7.3 Hz, H-12), 5.33 (1H, dd, J=8.3, 4.4 Hz, H-15), 5.31 (1H, m, H-133), 4.15 (1H, ddd, J=8.0, 5.0, 4.6 Hz, H-3), 3.80 (1H, m, H-7), 3.21 (1H, dq, J=6.0, 6.9 Hz, H-6), 2.89 (1H, d, J=5.0 Hz, 3-OH); 2.70 (3H, s, H-21), 2.65 (1H, ddd, J=15.8, 8.5, 8.3 Hz, H-14a), 2.42 (2H, m, H-2), 2.35 (1H, m, H-14b), 2.27 (1H, bd, 0.1=3.3 Hz, 7-OH), 2.13 (1H, m, H-11a), 2.09 (3H, d, J=1.2 Hz, H-27), 2.00 (1H, m, H-1 lb), 1.72 (1H, m, H-8), 1.40 (2H, m, H-10p), 1.37 (1H, m, H-9pa), 1.36 (2H, m, H-9a), 1.32 (3H, s, .H-23), 1.27 (3H, m, H-9b and H-10a), 1.13 (3H, d, J=6.9 Hz, H-24), 1.09 (3H, s, H-22), 0.94 (3H, d, J=6.9 Hz, H-25); 13C NMR (CDCl3, 75 MHz) δ 221.3 (s, C-5), 171.1 (s, C-1), 164.8 (s, C-20), 152.4 (s, C-18), 137.4 (s, C-16), 133.8 (d, C-12), 124.6 (d; C-13), 120.0 (d, C-17), 116.2 (d, C-19), 78.8 (d, C-15), 74.9 (d, C-7), 74.7 (d, C-3), 51.6 (s, C-4), 43.7 (d, C-6), 38.9 (t, C-2), 34.3 (d, C-8), 31.6 (t, C-14), 29.3 (t, C-9a, 28.6 (t, C-10β), 28.2 (t, C-10a), 26.6 (t, C-11), 24.8 (t, C-9β), 23.6 (q, C-22), 19.3 (q, C23), 19.3 (q, C-21), 16.5 (q, C-25), 15.5 (q, C:27), 13.7 (q, C-24); EIMS m/z 505 [M]+ XXX; HREIMS m/z 505.XXX (calcd. for C28H43NO5S, 505.XXX).
  • Epothilone I[0030] 2, (31): colorless amorphous solid; [α]22D -XXX (c XXX, MeOH); UV (MeOH) λmax nm (ε) XXX; IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 300 MHz) α 6.95 (1H, s, H-19), 6.53 (1H, bs, H-17), 5.40 (1H, m, H-12), 5.38 (1H, dd, J=9.8, 3.3 Hz, H-15), 5.37 (1H, m, H-133).4.21 (1H, ddd, 0.1=8.6, 3.8, 3.6 Hz, H-3), 3.85 (1H, ddd, J=8.5, 5.8, 2.2 Hz, H7), 3.18 (1H, dq, J=8.5, 7.0 Hz, H-6), 2.70 (3H, s, H-21), 2.65 (1H, ddd, J=15.2, 9.8, 9.0 Hz, H-14a), 2.51 (1H, d, J=3.6 Hz, 3-OH), 2.37 (2H, m, H-2), 2.32 (1H, bd, J=15.2 Hz, H-14b), 2.09 (3H, d, J=1.3 Hz, H-27), 2.07 (2H, m, H-11), 1.78 (1H, m, H-8), 1.65 (1H, d, J=5.8 Hz, 7-OH), 1.57 (1H, m, H-10βa), 1.44 (1H, m, H-10αa), 1.42 (1H, m, H-9β, 1.32 (3H, s, H-23), 1.21 (1H, m, H-10βb), 1.17 (3H, d, J=7.0 Hz, H-24), 1.13 (2H, m, H-9α),1.06 (3H, s, H-22), 0.95 (3H, d, J=7.0 Hz, H-25α), 0.91 (3H, d, J=6.5 Hz, H-25β), 0.68 (1H, m, H-10.b); 13C NMR (CDCl3, 100 MHz) δ 220.4 (s, C-5), 171.3) (s, C-1), XXX (s, C-20), 152.4 (s, C-18), 137.6 (s, C-16), 13)4.5 (d, C-12), 125.3) (d, C-13), 119.6 (d, C-17), 116.2 (d, C-19), 78.6 (d, C-15), 77.2 (d, C-7), 75.0 (d, C-3), 51.0 (s, C-4), 44.6 (d, C-6), 38.2 (t, C-2), 36.9 (t, C-9α), 34.5 (t, C-10α), 32.6 (d, C-8), 32.0 (t, C-14), 30.0 (d, C-9β), 27.4 (t, C-11), 26.6 (t, C-10p), 25.0 (q, C-22), 21.5 (q, C-25β), 19.3 (q, C-21), 17.9 (q, C-25α), 17.7 (q, C-23), 15.8 (q, C-24), 15.6 (q, C-27); EIMS m/z 519 MV XXX; HREIMS ,n/. 519.XXX (calcd. for C29H45NO5S, 519.XXX).
  • Epothilone I[0031] 3 (32): colorless amorphous solid; [α]22D -XXX (c XXX, MeOH); UV (MeOH) λmax nm (ε) XXX; IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.95 (1H, s, H-19), 6.52 (1H, bs, H-17), 5.32 (1H, dd, J=9.1, 3.0 Hz, H-15), 5.08 (1H, dd, J=8.˜, 3.9 Hz, H-13), 4.13 (1H, ddd, J=9.4,4.3, 3.2 Hz, H-3), 3.81 (1H, m, H-7), 3.18 (1H, dq, J=6.8, 7.0 Hz, H-6), 2.83 (1H, d, J=4.3 Hz, 3-OH), 2.70 (3H, s, H-21), 2.61 (1H, ddd, J=15.8,9.1, 8.5 Hz, H-14 a), 2.43 (1H, dd, J=14.0, 3.2 Hz, H-2a), 2.3 8 (2H, dd, J=14.0, 9.4 Hz, H-2b), 2.30 (1H, bd, J=15.8 Hz, H-14b), 2.16 (1H, ddd, J=14.1, 8.3, 7.4 Hz, H-11a), 2.08 (3H, d, J=1.0 Hz, H-27), 1.99 (1H, d, J=4.7 Hz, 7-OH), 1.92 (1H, ddd, J=14.1, 6.3, 6.3 Hz, H-1 Ib), 1.82 (1H, m, H-8), 1.67 (3H, s, H-26), 1.51 (1H, m, H-10pa), 1.40 (1H, m, H-9β), 1.33 (1H, m, H-10βb), 1.31 (3H, s, H-23), 1.27 (1H, M H-10αa), 1.23 (1H, m, H-9αa), 1.16 (3H, d, J=7.0 Hz, H-24), 1.10 (1H, m, H-9αb), 1.07 (3H, s, H-22), 0.95 (3H, d, J=7.0 Hz, H-25α), 0.92 (3H, d, J=6.5 Hz, H-25β), 0.75 (1H, m, H-10αb); EIMS m/z 533 M+XXX; HREIMS m/z 533.XXX (calcd. for C30H47NO5S, 533.XXX).
  • Epothilone 14 (33): colorless amorphous solid; [α][0032] 22D -XXX (c XXX, MeOH); UV (MeOH) λmax nm (ε) XXX; IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.95 (1H, s, H-19), 6.53 (1H, bs, H-17), 5.47 (1H, dt, J=11.1, 5.8 Hz, H-12), 5.33 (1H, ddd, J=9.2, 3.9, 0.5 Hz, H-15), 5.33 (1H, m, H-13), 4.09 (1H, dddd, J=9.6, 8.1, 4.5, 3.3 Hz, H-3), 3.83 (1H, m, H-7), 3.57 (1H, bs, 3-OH), 2.89 (1H, dq, J=7.4, 7.1 Hz, H-6), 2.83 (1H, dq, J=8.1, 7.1 Hz, H-4), 2.70 (3H, s, H-21), 2.64 (1H, m, H-14a), 2.42 (1H, dd, J=14.2, 3.3 Hz, H-2a), 2.43 (1H, dd, J=14.2, 9.6 Hz, H-2b), 2.30 (1H, m, H-14b), 2.10 (3H, d, J=1.3 Hz, H-27), 2.09 (2H, m, H-11), 1.81 (1H, m, H-8), 1.74 (1H, bd, J=5.6 Hz, 7-OH), 1.53 (1H, m, H-10βa), 1.49 (1H, m, H-9β), 1.47 (1H, m, H-10αa), 1.27 (1H, m, H-10βb), 1.24 (1H, m, H-9αa) 1.17 (3H, d, J=7.1 Hz, H-23), 1.14 (1H, m, H-9αb) 1.08 (3H, d, J=7.1 Hz, H-24), 0.97 (3H, d, J=6.9 Hz,H-25α), 0.91 (3H, d, J=6.5 Hz, H-25β), 0.79 (1H, m, H-10αb); 13C NMR (CDCl3, 100 MHz) δ 217.0 (s, C-5), 170.8 (s, C-1), 164.8 (s, C-20), 152.4 (s, C-18), 137.1 (s, C-16), 134.6 (d, C-12), 124.7 (d, C-13), 120.2 (d, C-17), 116.4 (d, C-19), 78.7 (d, C-15), 76.4 (d, C-7), 71.3 (d, C-3), 50.7 (d, C4), 50.1 (d, C-6), 40.7 (t, C-2), 38.5 (t, C-9α), 35.5 (t, C-10α), 33.4 (d, C-8), 31.8 (t, C-14), 30.0 (d, C-9β), 27.2 (t, C-11), 26.7 (t, C-10β), 21.4 (q, C-25βp), 19.3 (q, C-21), 18.2 (q, C-25α), 15.4 (q, C-27), 14.4 (q, C-24), 13.1 (q, C-23); EIMS m/z 505 [M]+ XXX; HREIMS m/z 505.XXX (calcd. for C28H43NO5S, 505.XX.X).
  • Epothilone 15, (34): colorless amorphous solid; [α]22D -XXX (c XXX, MeOH); UV (MeOH) λ[0033] max nm (ε) XXX; IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.97 (1H, s, H-19), 6.52 (1H, bs, H-17), 5.32 (1H, dd, J=7.1, 6.2 Hz, H-15), 5.03 (1H, dd, J=8.4, 5.0 Hz, H-13), 4.05 (1H, dddd, J=7.5, 7.2, 5.9, 4.6 Hz, H-3), 3.91 (1H, m, H-7), 3.17 (1H, d, J=5.9 Hz, 3-OH), 2.94 (1H, d q, J=7.2, 7.1 Hz, H-4), 2.87 (1H, dq, J=6.5, 6.9 Hz, H-6), 2.70 (3H, s, H-21), 2.62 (1H, dd, J=14.6, 4.6 Hz, H-2a), 2.60 (1H, M, H-14a), 2.53 (1H, dd, J=14.6, 7.5 Hz, H-2b), 2.31 (1H, m, H-14b), 2.10 (3H, d, J=1.1 Hz, H-27), 2.10 (1H, M, H-11a), 2.02 (1H, m, H-I I b), 1.97 (1H, bd, 1=5.6 Hz, 7-OH), 1.84 (1H, m, H-8), 1.66 (3H, s, H-26), 1.55 (1H, m, H-9p) 1.49 (1H, m, H-100a), 1.39 (1H, m, H-100b), 1.33. (1H, m, H-10αa), 1.31 (1H, m, H-9α), 1.15 (3H, d, J=7.1 Hz, H-23), 1.12 (1H, m, H-9αb), 1.11 (3H d, J=6.9 Hz, H-24), 0.97 (3H, d, J=6.9 Hz,H-25α), 0.94 (1H, m, H-10αb), 0.93 (3H, d, J=6.6 Hz, H-25p); EIMS m/z 519 μl+XXX; HREIMS ink 519.XXX (calcd. for C29H45NO5S,519.XXX).
  • Epothilone I[0034] 6 (35): colorless amorphous solid; [C]22D -XXX (c XXX, MeOH); UV (MeOH) λmax nm (ε) XXX; IR (KBr) νmax XXX cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.97 (1H, s, H-19), 6.52 (1H, bs, H-1 7), 5.24 (1H, dd, J=6.9, 6.9 Hz, H-15), 5.02 (1H, dd, J=8.8, 5.2 Hz, H-13), 4.22 (1H, tdd, J=6.1, 5.6, 4.8 Hz, H-3), 3.76 (1H, ddd, J=6.1, 5.7, 5.6 Hz, H-7), 3.13 (1H, d, J=5.6 Hz, 3-OH), 3.05 (1H, dq, J=4.8, 7.0 Hz, H-4), 2.79 (1H, dq, J=5.6, 6.9 Hz, H-6), 2.70 (3H, s, H-21), 2.62 (1H, m, H-14a), 2.57 (2H, d, J=6.1 Hz, H-2a), 2.30 (1H, m, H-14b), 2.08 (3H, d, J=1.0 Hz, H-27), 2.02 (2H, m, H-11), 1.73 (1H, d, J=6.1 Hz, 7-OH), 1.69 (1H, m, H-8), 1.66 (3H, s, H-26), XXX (H-9α, H-9β, H-10α, H-10β), 1.21 (3H, d, J=7.0. Hz, H-22), 1.16 (3H, d, J=6.9 Hz, H-24), 0.94 (3H, d, J=6.9 Hz,H-25α), 0.91 (3H, d, J=6.4 Hz, H-25β); EIMS m/z 519 [M]+ XXX; HREIMS m/z 519.XXX (calcd. for C29H45NO5S, 519.XXX).
  • Epothilone K (36): colorless amorphous solid; [α][0035] 22D -7 (c 0.08, MeOH); UV (MeOH) λmax nm (ε) 212 (16700), 248 (12500); IR (KBr) νmax3431, 2963, 2927, 2856, 1731, 1712, 1262, 1093, 1021, 802 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.95 (1H, s, H-19), 6.51 (1H, bs, H-17), 5.49 (3H, m, H-15, H-13, and H-12), 4.04 (1H, dddd, J=7.9, 7.6, 6.9, 3.3 Hz, H-3), 3.36 (1H, dq, J=6.9, 6.8 Hz, H-6), 2.83 (1H, d, J=7.6 Hz, 3-OH), 2.75 (1H, ddd, J=16.1, 6.6, 3.4 Hz, H-14a), 2.74 (1H, dd, J=15.3, 3.3 Hz, H-2a), 2.71 (3H, s, H-21), 2.58 (2H, m, H-14b and H-8), 2.50 (1H, dd, J=15.3, 7.9 Hz, H-2b), 2.29 (1H, m, H-11a), 2.10 (1H, m, H-1 lb), 2.09 (311, d, J=0.7 Hz, H-27), 1.78 (1H,-m, H-9a), 1.65 (1H, m, H-10a ), 1.48 (1H, m, H-10b), 1.18 (1H, m, H-9b), 1.15 (3H, d, J=6.8 Hz, H-22), 1.03 (3H, d, J=6.5 Hz, H-25); EIMS m/z 405 [M]+ (38), 317 (12), 260 (9), 232 (10), 204 (14), 190 (16), 168 (100), 164 (30), 151 (28); HREIMS m/z 405.″X (calcd. for C26H39NO5S, 405.XXX).
  • (37): colorless amorphous solid; [α]22D -27.5 (c 0.4, MeOH); UV (MeOH) λ[0036] max nm (ε) 211 (16100), 247 (12100); IR (KBr) νmax 3431, 2967, 2929, 2875, 1704, 1462, 1381, 1010 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.94 (1H, s, H-19), 6.55 (1H, bs, H-17), 5.56 (1H, dtt, J=10.8, 7.3, 1.4 Hz, H-12), 5.39 (1H, dtt, J=10.8, 7.3, 1.4 Hz, H-13), 4.17 (1H, t, J=6.6 Hz, H-15), 3.50 (1H, ddd, J=8.7,2.6,2.6 Hz, H-7), 3.10 (1H, d, J=2,6,7-OH), 2.90 (1H, dq, J=2.6, 7.2 Hz, H-6), 2.77 (1H, sep, J=6.9 Hz, H-4), 2.70 (3H, s, H-21), 2.40 (2H, m, H-14), 2.07 (2H, m, H-11), 2.04 (3H, d, J=1.1 Hz, H-27), 1.78 (1H, bs, 15-OH), 1.74 (1H, m, H-9a),.1.50 (1H, m, H-8), 1.46 (1H, m, H-10a ), 1.27 (1H, m, H-10b), 1.11 (1H, m, H-9b), 1.094 (3H, d, J=6.9 Hz, H-23), 1.089 (3H, d, J=6.9 Hz, H-22), 1.08 (3H, d, J=7.2 Hz, H-24), 0.82 (3H, d, J=6.7 Hz, H-25); 13C NMR (CDCl3, 100 MHz) δ 220.5 (s, C-5), 164.6 (s, C-20), 152.9 (s, C-18), 141.5 (s, C-16), 133.4 (d, C-12), 125.0 (d, C-13), 119.2 (d, C-17), 115.6 (d, C-19), 77.2 (d, C-15), 74.9 (d, C-7), 44.9 (d, C-6), 40.0 (d, C-4), 35.5 (d, C-8), 33.5 (t, C-14), 32.3 (t, C-9), 27.9 (t, C-11), 26.9 (t, C-10), 19.2 (q, C-21), 18.6 (q, C-23), 18.1 (q, C-22), 15.6 (q, C-25), 14.4 (q, C-27), 9-3 (q, C-24); EIMS m/z 407 [M]+ (0.1), 204 (0.8), 168 (100), 140 (3.4); HREIMS m/z 407.XXX (calcd. for C23H37NO3S, 407.XXX).
  • (38): colorless amorphous solid; [α][0037] 22D+25.0 (c 0.5, MeOH); UV (MeOH) λmax nm (ε) 212 (17700), 247 (13400); IR (KBr) νmax 3427, 2971, 2933, 2878, 2858, 1709, 1457, 1377, 1186,1023 cm−1; 1H NMR (CDCl3, 300 MHz) δ 6.95 (1H, s, H-19), 6.55 (1H, bs, H-17), 5.52 (1H, dtt, J=10.9, 7.2, 1.4 Hz, H-12), 5.39 (1H, dtt, J=10.9, 7.1, 1.2 Hz, H-13), 4.18 (1H, ddt, J=3.4, 0.4, 6.7 Hz, H-1 5), 2.71 (3H, s, H-21), 2.51 (1H, bq, J=6.8 Hz, H-8), 2.48 (1H, dq, J=17.7, 7.4 Hz, H-6a), 2.41 (1H, dq, 1=17.7, 7.2 Hz, H-6b), 2.39 (2H, ddd, J=7.1, 6.7, 1.4 Hz, H-14), 2.06 (2H, ddt, 7.2, 1.2, 7.0 Hz, H-11), 2.05 (3H, d, J=1.4 Hz, H-27), 1.81 (1H, d, J=3.4 Hz, 15-01-1), 1.66 (1H, m, H-9a), 1.32 (1H, m, H-9b), 1.31 (2H, m, H-10), 1.06 (3K d, J=6JHz, H-25), 1.04 (3H, dd, J=7.4, 7.2 Hz, H-24); 13C NMR (CDCl3, 75 MHz) δ 215.3 (s, C-7), 164.6 (s, C-20), 152.9 (s, C-18), 141.5 (s, C-16), 132.7 (d, C-12), 125.3 (d, C-13), 119.2 (d, C-17), 115.6 (d, C-19), 77.2 (d, C-15), 46.0 (d, C-8), 34.3 (t, C-14), 33.5 (t, C-6), 32.7 (t, C-9), 27.5 (t, C-11), 27.3 (t, C-10), 19.2 (q, C-21), 16.5 (q, C-25), 14.4 (q, C-27), 7.8 (q, C-24); EIMS m/z 335 [M]+ (2), 317 (4), 170 (27), 169 (67), 168 (100), 140 (20); HREIMS m/z 335.1912 (calcd. for C19H29NO2S, 335.1919).
  • (39): colorless amorphous solid; [α][0038] 22D+26.4 (c 0.27, MeOH); UV (MeOH) λmax nm (ε) 203 (19100), 244 (12500); IR (KBr) νmax3430, 2970, 2934, 2877, 1710, 1458, 1377, 1184 cm−1; 1H NMR (CDCl3, 400 MHz) δ 6.94 (1H, s, H-19), 6.55 (1H, bs, H-17), 5.17 (1H, t, J=7.3 Hz, H-13), 4.13 (1H, m, H-15), 2.70 (3H, s, H-21), 2.51 (1H, bq, J=6.8 Hz, H-8), 2.47 (1H, dq, J=17.7, 7.2 Hz, H-6a), 2.41 (1H, dq, J=17.7, 7.2 Hz, H-6b), 2.33 (2H, bdd, J=7.3, 6.8 Hz, H-14), 2.05 (3H, d, J=1.2 Hz, H-27), 2.03 (2H, m, H-11), 1.71 (1H, d, J=3.2 Hz, 15-OH), 1.69 (3H, d, J=1.3 Hz, H-26), 1.62 (1H, m, H-9a), 1.32 (3H, m, H-10 and H-9b), 1.06 (3H, d, J=6.9 Hz, H-25), 1.03 (3H, t, J=7.2 Hz, H-24); EIMS m/z 349 [M]+ (0.7), 331 (1.7), 168 (100), 140 (5.1); HREIMS m/., 349.XXX (calcd. for C20H31NO2S, 349.XXX).
    TABLE 1
    Activity of epothilones and compounds (1) to (39) against mouse
    fibroblasts (L929, IC 50/ng/ml)
    Epothilone
    Structural type Aγ Bγ Cγ Dγ trans Cγ
    Starting (1) 4 (2) 1-2 (14) 50-100 (15) 20 —
    epothilone
    21-Hydroxy (3) 10 (4) 1.5 — — —
    (E&F)
    Oxozoles (10) 6 (11) 1 (12) 120 (13) 11 —
    (G&H)
    (R)-4- (5) 20 — (16) 200 (17) 20 (28) 400
    Desmethyl (X1)
    (S)-4- (6) 7 — (10) 25-30 (19) 12 (29) 80
    Desmethyl (X2)
    6-Desmethyl — — (20 1500 — —
    (X3)
    8-Desmethyl — — (21) 800 — —
    (X4)
    8,9-Dehydro — — (22) 1500 (23) 200
    (X5)
    10,11-Dehydro — — (24) 120 — —
    (X6)
    14-Hydroxy — — (25) — —
    (X7)
    16-Desmethyl (7) 20 — (26) 250
    (X8)
    27-Hydroxy (8) 100 — (27) 200 — —
    (X9)
    21-Methyl — (9) 1.5 — — —
    (X10)
    Compound — — (36) 180
    Compound — — (37) 50 — —
    Compound — — (38) 2000 (39) 500 —

Claims (13)

What we claim is:
1. Epothilone of formula
Figure US20040049051A1-20040311-C00014
2. Epothilone of formula
Figure US20040049051A1-20040311-C00015
3. Epothilone of formula
Figure US20040049051A1-20040311-C00016
4. Epothilone of formula
Figure US20040049051A1-20040311-C00017
5. Epothilone of formula
Figure US20040049051A1-20040311-C00018
6. Epothilone of formula
Figure US20040049051A1-20040311-C00019
7. Epothilone of formula
Figure US20040049051A1-20040311-C00020
8. Epothilone of formula
Figure US20040049051A1-20040311-C00021
9. Epothilone of formula
Figure US20040049051A1-20040311-C00022
10. Epothilone of formula
Figure US20040049051A1-20040311-C00023
11. Epothilone of formula
Figure US20040049051A1-20040311-C00024
12. Compound of formula
Figure US20040049051A1-20040311-C00025
13. Compound of formula
Figure US20040049051A1-20040311-C00026
US10/457,098 1998-06-18 2003-06-06 Epothilone side components Abandoned US20040049051A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/457,098 US20040049051A1 (en) 1998-06-18 2003-06-06 Epothilone side components
US11/354,769 US7235669B2 (en) 1998-06-18 2006-02-15 Epothilone side components

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19826988.9 1998-06-18
DE19826988A DE19826988A1 (en) 1998-06-18 1998-06-18 Epothilone minor components
US09/719,932 US6624310B1 (en) 1998-06-18 1999-06-18 Epothilone minor constituents
US10/457,098 US20040049051A1 (en) 1998-06-18 2003-06-06 Epothilone side components

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09719932 Division 1999-06-18
US09/719,932 Division US6624310B1 (en) 1998-06-18 1999-06-18 Epothilone minor constituents
PCT/EP1999/004244 Division WO1999065913A2 (en) 1998-06-18 1999-06-18 Epothilone minor constituents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/354,769 Continuation US7235669B2 (en) 1998-06-18 2006-02-15 Epothilone side components

Publications (1)

Publication Number Publication Date
US20040049051A1 true US20040049051A1 (en) 2004-03-11

Family

ID=7871162

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/719,932 Expired - Lifetime US6624310B1 (en) 1998-06-18 1999-06-18 Epothilone minor constituents
US10/457,098 Abandoned US20040049051A1 (en) 1998-06-18 2003-06-06 Epothilone side components
US11/354,769 Expired - Lifetime US7235669B2 (en) 1998-06-18 2006-02-15 Epothilone side components

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/719,932 Expired - Lifetime US6624310B1 (en) 1998-06-18 1999-06-18 Epothilone minor constituents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/354,769 Expired - Lifetime US7235669B2 (en) 1998-06-18 2006-02-15 Epothilone side components

Country Status (11)

Country Link
US (3) US6624310B1 (en)
EP (2) EP1087975B1 (en)
JP (1) JP2002518397A (en)
AT (1) ATE248174T1 (en)
AU (1) AU757452B2 (en)
CA (1) CA2336189A1 (en)
DE (2) DE19826988A1 (en)
DK (1) DK1087975T3 (en)
ES (1) ES2207249T3 (en)
PT (1) PT1087975E (en)
WO (1) WO1999065913A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US20040102495A1 (en) * 1996-12-03 2004-05-27 Danishefsky Samual J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20070032534A1 (en) * 2002-08-23 2007-02-08 Danishefsky Samuel J Synthesis of epothilones, intermediates thereto and analogues thereof
US20080064634A1 (en) * 2006-05-01 2008-03-13 Markland Francis S Jr Combination therapy for treatment of cancer
US20090149516A1 (en) * 2002-08-23 2009-06-11 Danishefsky Samuel J Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof
US8685668B2 (en) 2005-02-11 2014-04-01 University Of Southern California Method of expressing proteins with disulfide bridges
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001368A1 (en) * 1984-09-03 1986-03-13 Macri, Lesley, Jean Cultivating apparatus
EP1367057B1 (en) * 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones E and F
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100851418B1 (en) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 Recombinant methods and materials for producing epothilone and epothilone derivatives
DE19908760A1 (en) * 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BR0009721A (en) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US20030176368A1 (en) * 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
ATE452896T1 (en) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-CYANOEPOTHILONE DERIVATIVES
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Open chain prolyl urea-related modulators of androgen receptor function
GB0230024D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
CA2588400A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising ixabepilone, and preparation thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
BRPI0718360A2 (en) 2006-12-04 2013-11-12 Univ Illinois "COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH COUPREDOXINS AND RICH DNA IN CPG"
WO2008147941A1 (en) * 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (en) 2011-07-09 2013-01-09 陈小平 Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
CN102993239A (en) 2011-09-19 2013-03-27 陈小平 Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6303342B1 (en) * 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6359140B1 (en) * 1997-02-25 2002-03-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Epothilones with modified side chain
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US20040014982A1 (en) * 2000-09-22 2004-01-22 Gerhard Hoefle Triazolo-epothilones
US20040092560A1 (en) * 2001-02-27 2004-05-13 Gerhard Hoefle Degradation of epothilones

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008849A1 (en) * 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Method for producing epothilones, and intermediate products obtained during the production process
EP1367057B1 (en) * 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones E and F
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
WO2000000485A1 (en) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
US5969159A (en) 1999-02-16 1999-10-19 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613912B2 (en) * 1995-11-17 2003-09-02 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6831076B2 (en) * 1995-11-17 2004-12-14 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6359140B1 (en) * 1997-02-25 2002-03-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Epothilones with modified side chain
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6303342B1 (en) * 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US20040014982A1 (en) * 2000-09-22 2004-01-22 Gerhard Hoefle Triazolo-epothilones
US20040092560A1 (en) * 2001-02-27 2004-05-13 Gerhard Hoefle Degradation of epothilones

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102495A1 (en) * 1996-12-03 2004-05-27 Danishefsky Samual J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050033059A1 (en) * 1996-12-03 2005-02-10 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8481575B2 (en) 1996-12-03 2013-07-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US8110590B2 (en) 2002-08-23 2012-02-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20070032534A1 (en) * 2002-08-23 2007-02-08 Danishefsky Samuel J Synthesis of epothilones, intermediates thereto and analogues thereof
US20090149516A1 (en) * 2002-08-23 2009-06-11 Danishefsky Samuel J Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8513429B2 (en) 2002-08-23 2013-08-20 Sloan-Kettering Insitute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7759374B2 (en) 2002-08-23 2010-07-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20100016385A1 (en) * 2003-11-04 2010-01-21 Bristol-Myers Squibb Company Process and formulation containing epothilones and analogs thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US8871227B2 (en) 2003-11-04 2014-10-28 Bristol-Myers Squibb Company Process and formulation containing epothilones and analogs thereof
US8685668B2 (en) 2005-02-11 2014-04-01 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US20080064634A1 (en) * 2006-05-01 2008-03-13 Markland Francis S Jr Combination therapy for treatment of cancer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity

Also Published As

Publication number Publication date
US7235669B2 (en) 2007-06-26
EP1087975A2 (en) 2001-04-04
CA2336189A1 (en) 1999-12-23
WO1999065913A3 (en) 2000-04-20
ATE248174T1 (en) 2003-09-15
US20060142584A1 (en) 2006-06-29
EP1087975B1 (en) 2003-08-27
AU757452B2 (en) 2003-02-20
DE19826988A1 (en) 1999-12-23
PT1087975E (en) 2004-01-30
US6624310B1 (en) 2003-09-23
EP1275648A1 (en) 2003-01-15
DK1087975T3 (en) 2003-12-01
WO1999065913A2 (en) 1999-12-23
AU4899599A (en) 2000-01-05
JP2002518397A (en) 2002-06-25
ES2207249T3 (en) 2004-05-16
DE59906782D1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
US20040049051A1 (en) Epothilone side components
US6359140B1 (en) Epothilones with modified side chain
US6831076B2 (en) Epothilons C and D, preparation and compositions
US7145018B2 (en) Method for synthesizing epothilones and epothilone analogs
JP4886578B2 (en) 6-Alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, methods for their production and their use in pharmaceutical formulations
AU757854B2 (en) Epothilone derivatives and their synthesis and use
MXPA01008328A (en) 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use.
US20060046997A1 (en) 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US7157595B2 (en) Degradation of epothilones
WO2001081341A2 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
US7939679B2 (en) Method for synthesis of ciguatoxin CTX1B and compounds useful for the synthesis of ciguatoxin CTX1B
EP0987268B1 (en) Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide
AU2002251030A1 (en) Degradation of epothilones and ethynyl substituted epothilones

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION